Immunovant: Pay

Immunovant paid its 5 named executives $30.3M in total in FY2025 (Mar).

Pay of each named executive

Peter Salzmann, M.D.Former Chief Executive Officer
FY2025 (Mar)
FY2022 (Mar)Not disclosed
2 years
Christopher Van TuylChief Legal Officer and Corporate Secretary
FY2025 (Mar)
1 year
Melanie GloriaChief Operating Officer
FY2025 (Mar)
1 year
Michael Geffner, M.D.Chief Medical Officer
FY2025 (Mar)
1 year
Eva Renee Barnett, M.B.A.Former Chief Financial Officer
FY2025 (Mar)
FY2024 (Mar)Not disclosed
FY2022 (Mar)Not disclosed
3 years

CEO pay against the pay peers

In FY2025 (Mar), the median CEO pay of the 6 peers with pay on file was $13.3M. The CEO of Immunovant was paid $10.7M, 19% below the median.

  1. 1Madrigal Pharmaceuticals
  2. 2BridgeBio Pharma
  3. 3Revolution Medicines
  4. 4Cytokinetics
  5. 5Immunovant
  6. 6Xenon Pharmaceuticals
  7. 7CRISPR Therapeutics AG
  8. 8Apellis PharmaceuticalsNot disclosed
  9. 9ArcellxNot disclosed
  10. 10Arrowhead PharmaceuticalsNot disclosed
  11. 11BiohavenNot disclosed
  12. 12Blueprint MedicinesNot disclosed
  13. 13NuvalentNot disclosed
  14. 14VaxcyteNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.